Cargando…

Traditional Chinese medicine in the era of immune checkpoint inhibitor: theory, development, and future directions

Immune checkpoint inhibitors (ICIs) have revolutionized cancer management and have been widely applied; however, they still have some limitations in terms of efficacy and toxicity. There are multiple treatment regimens in Traditional Chinese Medicine (TCM) that play active roles in combination with...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Yi-xuan, Wang, Shuo, Liu, Zhe-ning, Zhang, Xu, Hu, Zi-xin, Dong, Hui-jing, Lu, Xing-yu, Zheng, Jia-bin, Cui, Hui-juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199665/
https://www.ncbi.nlm.nih.gov/pubmed/37210537
http://dx.doi.org/10.1186/s13020-023-00751-7
_version_ 1785044979686572032
author Yu, Yi-xuan
Wang, Shuo
Liu, Zhe-ning
Zhang, Xu
Hu, Zi-xin
Dong, Hui-jing
Lu, Xing-yu
Zheng, Jia-bin
Cui, Hui-juan
author_facet Yu, Yi-xuan
Wang, Shuo
Liu, Zhe-ning
Zhang, Xu
Hu, Zi-xin
Dong, Hui-jing
Lu, Xing-yu
Zheng, Jia-bin
Cui, Hui-juan
author_sort Yu, Yi-xuan
collection PubMed
description Immune checkpoint inhibitors (ICIs) have revolutionized cancer management and have been widely applied; however, they still have some limitations in terms of efficacy and toxicity. There are multiple treatment regimens in Traditional Chinese Medicine (TCM) that play active roles in combination with Western medicine in the field of oncology treatment. TCM with ICIs works by regulating the tumor microenvironment and modulating gut microbiota. Through multiple targets and multiple means, TCM enhances the efficacy of ICIs, reverses resistance, and effectively prevents and treats ICI-related adverse events based on basic and clinical studies. However, there have been few conclusions on this topic. This review summarizes the development of TCM in cancer treatment, the mechanisms underlying the combination of TCM and ICIs, existing studies, ongoing trials, and prospects for future development.
format Online
Article
Text
id pubmed-10199665
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101996652023-05-22 Traditional Chinese medicine in the era of immune checkpoint inhibitor: theory, development, and future directions Yu, Yi-xuan Wang, Shuo Liu, Zhe-ning Zhang, Xu Hu, Zi-xin Dong, Hui-jing Lu, Xing-yu Zheng, Jia-bin Cui, Hui-juan Chin Med Review Immune checkpoint inhibitors (ICIs) have revolutionized cancer management and have been widely applied; however, they still have some limitations in terms of efficacy and toxicity. There are multiple treatment regimens in Traditional Chinese Medicine (TCM) that play active roles in combination with Western medicine in the field of oncology treatment. TCM with ICIs works by regulating the tumor microenvironment and modulating gut microbiota. Through multiple targets and multiple means, TCM enhances the efficacy of ICIs, reverses resistance, and effectively prevents and treats ICI-related adverse events based on basic and clinical studies. However, there have been few conclusions on this topic. This review summarizes the development of TCM in cancer treatment, the mechanisms underlying the combination of TCM and ICIs, existing studies, ongoing trials, and prospects for future development. BioMed Central 2023-05-20 /pmc/articles/PMC10199665/ /pubmed/37210537 http://dx.doi.org/10.1186/s13020-023-00751-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Yu, Yi-xuan
Wang, Shuo
Liu, Zhe-ning
Zhang, Xu
Hu, Zi-xin
Dong, Hui-jing
Lu, Xing-yu
Zheng, Jia-bin
Cui, Hui-juan
Traditional Chinese medicine in the era of immune checkpoint inhibitor: theory, development, and future directions
title Traditional Chinese medicine in the era of immune checkpoint inhibitor: theory, development, and future directions
title_full Traditional Chinese medicine in the era of immune checkpoint inhibitor: theory, development, and future directions
title_fullStr Traditional Chinese medicine in the era of immune checkpoint inhibitor: theory, development, and future directions
title_full_unstemmed Traditional Chinese medicine in the era of immune checkpoint inhibitor: theory, development, and future directions
title_short Traditional Chinese medicine in the era of immune checkpoint inhibitor: theory, development, and future directions
title_sort traditional chinese medicine in the era of immune checkpoint inhibitor: theory, development, and future directions
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199665/
https://www.ncbi.nlm.nih.gov/pubmed/37210537
http://dx.doi.org/10.1186/s13020-023-00751-7
work_keys_str_mv AT yuyixuan traditionalchinesemedicineintheeraofimmunecheckpointinhibitortheorydevelopmentandfuturedirections
AT wangshuo traditionalchinesemedicineintheeraofimmunecheckpointinhibitortheorydevelopmentandfuturedirections
AT liuzhening traditionalchinesemedicineintheeraofimmunecheckpointinhibitortheorydevelopmentandfuturedirections
AT zhangxu traditionalchinesemedicineintheeraofimmunecheckpointinhibitortheorydevelopmentandfuturedirections
AT huzixin traditionalchinesemedicineintheeraofimmunecheckpointinhibitortheorydevelopmentandfuturedirections
AT donghuijing traditionalchinesemedicineintheeraofimmunecheckpointinhibitortheorydevelopmentandfuturedirections
AT luxingyu traditionalchinesemedicineintheeraofimmunecheckpointinhibitortheorydevelopmentandfuturedirections
AT zhengjiabin traditionalchinesemedicineintheeraofimmunecheckpointinhibitortheorydevelopmentandfuturedirections
AT cuihuijuan traditionalchinesemedicineintheeraofimmunecheckpointinhibitortheorydevelopmentandfuturedirections